


Pseudoginsenoside F11

Cat. No.:	HY-N0541
CAS No.:	69884-00-0
Molecular Formula:	C ₄₂ H ₇₂ O ₁₄
Molecular Weight:	801.01
Target:	Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (62.42 mM; ultrasonic and warming and heat to 60°C)
H₂O : 0.67 mg/mL (0.84 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.2484 mL	6.2421 mL	12.4842 mL
	5 mM	0.2497 mL	1.2484 mL	2.4968 mL
	10 mM	0.1248 mL	0.6242 mL	1.2484 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Pseudoginsenoside F11 (Ginsenoside A1), a component of *Panax quinquefolium* (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Biochemical experiments revealed that Pseudoginsenoside F11 (Ginsenoside A1) could inhibit diprenorphine (DIP) binding

with an IC₅₀ of 6.1 μM and reduced the binding potency of morphine in Chinese hamster ovary (CHO)-μ cells^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

One in vivo model of cisplatin-induced acute renal failure was performed. The results showed that pretreatment with Pseudoginsenoside F11 (Ginsenoside A1) reduced cisplatin-elevated blood urea nitrogen and creatinine levels, as well as ameliorated the histopathological damage [1]. We tested the effects of Pseudoginsenoside F11 (Ginsenoside A1) on morphine-induced development of behavioral sensitization and alterations in glutamate levels in the medial prefrontal cortex (mPFC) in freely moving mice by using in vivo microdialysis. As the results shown, Pseudoginsenoside F11 (Ginsenoside A1) antagonized the development of behavioral sensitization and decrease of glutamate in the mPFC induced by morphine^[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Front Pharmacol. 29 April 2021.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Wang H, et al. The pseudoginsenoside F11 ameliorates cisplatin-induced nephrotoxicity without compromising its anti-tumor activity in vivo. Scientific Reports [2014, 4:4986]
- [2]. Li Zhu, et al. Pseudoginsenoside-F11 attenuates morphine-induced signalling in Chinese hamster ovary-μ cells. Neuroreport, 25 May 2001 - Volume 12 - Issue 7 - pp 1453-1456
- [3]. Yue Hao, et al. Pseudoginsenoside-F11 decreases morphine-induced behavioral sensitization and extracellular glutamate levels in the medial prefrontal cortex in mice. Pharmacology Biochemistry and Behavior Volume 86, Issue 4, April 2007, Pages 660–666
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA